Flow Cytometry Shared Resource (FCSR)

流式细胞术共享资源 (FCSR)

• 批准号: 10619446
• 负责人: Zoran Galic
• 金额: $ 27.46万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-12-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10619446
• 关键词: Adjuvant; BRAF gene; Biological Assay; Biological Markers; Blood Cells; Cancer Center; Cancer Center Support Grant; Cell Separation; Cells; Charge; Clinic; Clinical; Collaborations; Communities; Comprehensive Cancer Center; Computer Workstations; Consultations; Control Groups; Core Facility; Cytometry; Data Analyses; Dendritic Cell Vaccine; Development; Doctor of Philosophy; Education; Educational process of instructing; Educational workshop; Ensure; Equipment; Evolution; Experimental Designs; Flow Cytometry; Flow Cytometry Shared Resource; Glioma; Hour; Human Resources; Image; Image Cytometry; Immune checkpoint inhibitor; Immunofluorescence Immunologic; In Vitro; Individual; Industry; Institution; Instruction; Investigation; Investments; Journals; Knowledge; Laboratories; Lasers; Leadership; MEKs; Magnetism; Manufacturer; Measurement; NCI Center for Cancer Research; Neoadjuvant Therapy; Patients; Phase I Clinical Trials; Probability; Protocols documentation; Publications; Randomized; Reagent; Research; Research Personnel; Research Project Grants; Resource Sharing; Running; Schedule; Secure; Services; Signal Pathway; Sorting; Specialist; Speed; Technology; Training; Tumor-Infiltrating Lymphocytes; Update; Work; Zoran; analytical tool; anticancer research; base; cell analyzer; cell preparation; cell separator; cost; experience; high end computer; inhibitor; instrument; instrumentation; large datasets; medical schools; meetings; melanoma; member; mouse model; mutant; new technology; novel; operation; pembrolizumab; posters; preclinical study; programs; randomized trial; technology development; tool; web site

FLOW CYTOMETRY SHARED RESOURCE (FCSR) ABSTRACT The UCLA Jonsson Comprehensive Cancer Center (JCCC) Flow Cytometry Shared Resource (FCSR) provides continuously updated, state-of-the-art instrumentation, expertise, and training at a reduced recharge rate to JCCC investigators whose research requires flow cytometry, mass cytometry, imaging cytometry, or cell sorting. The FCSR is one of the longest running core facilities at UCLA and it has been servicing the needs of the JCCC cancer research community since its inception in 1988. In 2015, Zoran Galic, PhD (ZY) became the FCSR Director and he oversees all of the operations of the facility. Alejandro Garcia, PhD, FCSR Co-Director and Facility Manager, is responsible for FCSR daily operations and assists Galic with long-term core planning. The FCSR currently houses an ImageStream imaging cytometer, a Helios mass cytometer, an Attune NxT flow cytometer, two LSR II cell analyzers, an LSR Fortessa cell analyzer, three Aria high-speed cell sorters, one of which is enclosed in a biocontainment hood, and a RoboSep magnetic cell separator. The FCSR also established a separate office for data analysis with two high-end computer workstations capable of processing large data sets generated by the ImageStream imaging cytometer. FCSR personnel have >80 years of combined flow cytometry experience and they provide expert guidance to JCCC investigators through one-on-one consultations, educational classes, an information-rich website, and “how-to” poster presentations. Workshops, seminars, and tutorials organized by the FCSR ensure that researchers remain on the leading edge of cytometry. The FCSR has a broad user base and during 2013 – 2018, the FCSR supported many JCCC investigator projects from all six JCCC Research Programs. JCCC member usage is 78% of the total Shared Resource usage. FCSR support activities helped to enable 333 publications, of which 175 (53%) were in high-impact (IF ≥10, or field leading) journals. FCSR leaders work with the Dean’s office in the David Geffen School of Medicine and additional centers on campus to contain costs and provide high quality services for JCCC investigator studies. During the prior project period, the FCSR supported numerous JCCC research teams to advance impactful preclinical studies to the clinic. One inter-programmatic investigation showed that a combination of an immune checkpoint inhibitor with BRAF plus MEK signaling pathway inhibitors in a mouse model of BRAF-mutant melanoma was superior to either treatment alone. Based on these results, two Phase I clinical trials and three larger industry sponsored randomized trials are underway. Separately, the FCSR supported intra-programmatic preclinical studies on checkpoint inhibitors and dendritic cell vaccines in a mouse model of intracranial glioma. Based on this work a randomized, multi-institution trial established that neoadjuvant pembrolizumab significantly extended patients overall survival compared to a control group that received pembrolizumab only as adjuvant. In both of these study examples, the FCSR sorted tumor-infiltrating lymphocytes and provided the instrumentation and expert guidance for analysis of these cells and peripheral blood cells. Page 1 of 1

流式细胞仪共享资源（FCSR） 摘要 UCLA Jonsson综合癌症中心（JCCC）流式细胞术共享资源（FCSR）提供 不断更新的最先进的仪器、专业知识和培训， 研究需要流式细胞术、质谱细胞术、成像细胞术或细胞分选的JCCC研究者。 FCSR是加州大学洛杉矶分校运行时间最长的核心设施之一，它一直为JCCC的需求提供服务 自1988年成立以来，癌症研究社区。2015年，Zoran Galic博士（ZY）成为FCSR 他负责监管整个机构的运作。Alejandro Garcia博士，FCSR联合主任， 设施经理，负责FCSR的日常运营，并协助Galic进行长期的核心规划。的 FCSR目前拥有ImageStream成像细胞仪、Helios质谱细胞仪、Attune NxT流式细胞仪、 流式细胞仪，两台LSR II细胞分析仪，一台LSR Fortessa细胞分析仪，三台Aria高速细胞分选仪，一台 它被封闭在生物防护罩中，还有RoboSep磁性细胞分离器。FCSR还建立了 一个独立的数据分析办公室，配备两个能够处理大量数据的高端计算机工作站 由ImageStream成像细胞仪生成的组。FCSR员工拥有超过80年的综合流动经验 他们通过一对一的方式为JCCC研究人员提供专家指导 咨询、教育课程、信息丰富的网站和"如何做"海报展示。讲习班、 FCSR组织的研讨会和教程确保研究人员保持在细胞计数的前沿。 FCSR拥有广泛的用户基础，在2013 - 2018年期间，FCSR支持了许多JCCC调查员项目 来自六个JCCC研究项目。JCCC成员的使用量占共享资源总使用量的78%。fcsr 支持活动帮助促成了333份出版物，其中175份（53%）是高影响力出版物（IF ≥ 10，或外地出版物 领导）期刊。FCSR领导人与大卫格芬医学院院长办公室合作， 在校园内增加中心，以控制成本，并为JCCC调查研究提供高质量的服务。 在上一个项目期间，FCSR支持了许多JCCC研究团队，以推动有影响力的 临床前研究到临床。一项跨项目调查显示， 检查点抑制剂与BRAF加MEK信号传导通路抑制剂在BRAF突变小鼠模型中的联合应用 黑色素瘤的上级效果优于单独治疗。基于这些结果，两项I期临床试验和三项 更大的工业赞助的随机试验正在进行中。另外，财务和社会责任委员会支持方案内的 在颅内胶质瘤小鼠模型中进行检查点抑制剂和树突状细胞疫苗的临床前研究。 基于这项工作，一项随机、多机构试验确定，新辅助帕博利珠单抗显著 与仅接受pembrolizumab作为辅助治疗的对照组相比，延长了患者的总生存期。 在这两个研究实施例中，FCSR分选肿瘤浸润性淋巴细胞，并提供了肿瘤浸润性淋巴细胞。 分析这些细胞和外周血细胞的仪器和专家指导。 页1的1